AstraZeneca PLC

NYSE:AZN

Drug Manufacturers - General

Healthcare
$178.76 -1.71%

-$3.04 today

Market cap
$277.23B
Beta
0.21
P/E (TTM)
25.7
EPS (TTM)
$6.75
Dividend yield
1.80%
52W Low $137.22High $212.71

Volume 2.54M

Average 1.96M

AZN Pre-Tax Margin

Income before tax as a percentage of revenue.

AstraZeneca PLCNYSE: AZN

Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026

Pre-tax margin widens to 24.4%

Pre-tax margin was 24.4% in Q3 FY2026, up 3.1 pp from a year earlier. On a trailing-twelve-month basis it was 21.3%, up 1.6 pp year over year. Over 3 fiscal years it widened by 15.5 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
24.4%+6.2 pp QoQ
Last fiscal yearDec 2025
21.1%+5.0 pp YoY
LTMSep 2026
21.3%+1.6 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.1 pp——
1 year+5.0 pp——
3 years+15.5 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
21.1%
Year-over-year change
+5.0pp

Pre-Tax Margin vs competitors

How AZN compares with its peers on the latest reported figures

  • AZN's LTM Sep 2026 pre-tax margin of 21.3% is the 6th highest of the 10 companies compared; the peer median is 24.2%.
  • Its year-over-year change of +1.6 pp is the 5th highest of 10, against a peer median of +0.0 pp.
  • Over three fiscal years its change of +15.5 pp compares with a peer median of +3.2 pp.
AZN Competitors Peer median
Pre-Tax Margin for AZN and competitors
Company Period LTM level YoY 3-year change
NVONovo Nordisk A/SLTM Jun 202645.2% +0.0 pp+3.2 pp
LLYEli Lilly and CompanyLTM Jun 202642.2% +10.5 pp+15.6 pp
NVSNovartis AGLTM Jun 202627.9% -0.4 pp+13.5 pp
AMGNAmgen Inc.LTM Jun 202627.0% +5.7 pp-3.5 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202624.2% +10.4 pp+2.6 pp
AZNAstraZeneca PLCLTM Sep 202621.3% +1.6 pp+15.5 pp
ABBVAbbVie Inc.LTM Sep 202619.4% +16.6 pp-12.4 pp
JNJJohnson & JohnsonLTM Sep 202617.9% -16.3 pp+10.4 pp
MRKMerck & Co., Inc.LTM Jun 20269.0% -21.1 pp+4.7 pp
PFEPfizer Inc.LTM Jun 20266.6% -9.9 pp-22.3 pp
Peer median (excluding AZN) 24.2%+0.0 pp+3.2 pp

Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.42B44.35B45.81B54.07B58.74B
Cost of Revenue12.44B12.39B8.27B10.21B10.63B
Gross Profit24.98B31.96B37.54B43.87B48.11B
Gross Margin66.8%72.1%82.0%81.1%81.9%
Research & Development9.74B9.76B10.94B13.58B14.23B
Selling, General & Admin15.59B17.98B18.22B20.22B20.51B
Operating Expenses23.92B28.2B29.35B33.86B34.36B
Depreciation & Amortization4.1B5.25B4.93B5.07B5.73B
EBITDA5.11B9.09B13.42B15.44B19.83B
EBITDA Margin13.7%20.5%29.3%28.6%33.8%
Operating Income1.06B3.76B8.19B10B13.74B
Operating Margin2.8%8.5%17.9%18.5%23.4%
Interest Income43M81M301M345M360M
Interest Expense1.28B1.33B1.59B1.68B1.69B
Other Income / Expenses(1.32B)(1.26B)(1.29B)(1.31B)(1.34B)
Income Before Tax(265M)2.5B6.9B8.69B12.4B
Pre-Tax Margin-0.7%5.6%15.1%16.1%21.1%
Income Tax Expense(380M)(792M)938M1.65B2.17B
Net Income112M3.29B5.96B7.04B10.26B
Net Margin0.3%7.4%13.0%13.0%17.5%
EPS (Basic)0.082.123.814.546.60
EPS (Diluted)0.082.113.814.506.54
Weighted Avg Shares1.42B1.55B1.56B1.55B1.55B
Weighted Avg Shares (Diluted)1.43B1.56B1.56B1.56B1.56B

AstraZeneca PLC

NYSE:AZN

Intrinsic Alpha fair value

Locked

Current Price

$178.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.